Glaxosmithkline
This article is outside of Ballotpedia's coverage scope and does not receive scheduled updates. If you would like to help our coverage scope grow, consider donating to Ballotpedia.
| Glaxosmithkline | |
 | |
| Basic facts | |
| Location: | Philadelphia, Pa. |
| Top official: | Andrew Witty, CEO |
| Year founded: | 2001 |
| Website: | Official website |
As of 2016, Glaxosmithkline was a global healthcare company based in the United Kingdom that "researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare." The company's U.S. headquarters was located in Philadelphia, Pennsylvania.[1][2]
Mission
According to the company's website, Gaxosmithkline had the following mission statement: "Our mission is to help people do more, feel better, live longer."[4]
Background
Glaxosmithkline was formed in 2001 through the merger of GlaxoWellcome plc and SmithKline Beecham plc. As a global healthcare company, Glaxosmithkline "researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare." The company's product portfolio included treatments for HIV/AIDS, malaria, and tuberculosis as well as consumer brands, including Sensodyne, Aquafresh, and Tums.[1][5]
As of October 2016, Glaxosmithkline maintained commercial, research, and manufacturing operations in over 150 countries.[6]
Work
Lobbying
The following table displays Glaxosmithkline's federal lobbying expenditures according to the Center for Responsive Politics:[7]
| Federal lobbying expenditures for Glaxosmithkline, 2010-2015 | ||
|---|---|---|
| Year | Total expenditures | |
| 2015 | $4,075,000 | |
| 2014 | $4,370,000 | |
| 2013 | $3,720,000 | |
| 2012 | $4,920,000 | |
| 2011 | $5,445,000 | |
| 2010 | $6,070,000 | |
Political activity
As of 2016, Glaxosmithkline aimed to support its public policy priorities through participation in the U.S. political process. According to the company's website, Glaxosmithkline's priorities aimed "to advance a supportive environment that enables patients and consumers to benefit from value-adding medicines, vaccines and healthcare products."[8]
Glaxosmithkline made political contributions to federal candidates through GSK PAC, its voluntary, employee-funded political action committee. As of 2016, the company did not make direct corporate contributions to state or local candidates or political committees, even when permissible by law. Glaxosmithkline was a member of 501(c)(6) professional industry and trade organizations that aim to advocate for the interests of the pharmaceutical industry, such as Pharmaceutical Research and Manufacturers of America (PhRMA).[8][9]
Ballot measure activity
Glaxosmithkline took positions on ballot measures that seek to impact prescription drug pricing. The company opposed the 2016 California Drug Price Standards Initiative (Proposition 61), which proposed to regulate drug prices by requiring state agencies to pay the same prices for prescription drugs as the U.S. Department of Veterans Affairs (VA).[3]
Overview of ballot measure support and opposition
The following table details Glaxosmithkline's ballot measure stances available on Ballotpedia:
| Ballot measure support and opposition for Glaxosmithkline | |||
|---|---|---|---|
| Ballot measure | Year | Position | Status |
| California Proposition 61, Drug Price Standards (2016) | 2016 | Opposed[3] |  Defeated
|
| California Proposition 78, Prescription Drug Discount Program Initiative (2005) | 2005 | Supported[10] | Defeated
|
Leadership
The following individuals held leadership positions with Glaxosmithkline in October 2016:[11]
- Sir Andrew Witty, Chief executive officer
- Emma Walmsley, Chief executive officer designate
- Roger Connor, President, global manufacturing and supply
- Luc Debruyne, President, global vaccines
- Simon Dingemans, Chief financial officer
- Nick Hirons, Senior vice president, global ethics and compliance
- Abbas Hussain, President, global pharmaceuticals
- Brian McNamara, CEO, GSK Consumer Healthcare
- David Redfern, Chief strategy officer
- Moncef Slaoui, Chairman, global vaccines
- Claire Thomas, Senior vice president, human resources
- Phil Thomson, Senior vice president, communications and government affairs
- Dan Troy, Senior vice president and general counsel
- Patrick Vallance, President, pharmaceuticals R&D
Recent news
The link below is to the most recent stories in a Google news search for the terms Glaxosmithkline. These results are automatically generated from Google. Ballotpedia does not curate or endorse these articles.
See also
- California Proposition 61, Drug Price Standards (2016)
- California 2016 ballot measures
- Healthcare policy in California
External links
Footnotes
- ↑ 1.0 1.1 LinkedIn, "Glaxosmithkline," accessed October 7, 2016
- ↑ Glaxosmithkline United States, "Contact us," accessed October 7, 2016
- ↑ 3.0 3.1 3.2 California Fair Political Practices Commission, "November 2016 General Election," accessed October 2, 2016, 2016
- ↑ Glaxosmithkline, Our mission and strategy," accessed October 7, 2016
- ↑ Glaxosmithkline, "Our history," accessed October 7, 2016
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedAbout - ↑ Center for Responsive Politics, "Glaxosmithkline," accessed October 26, 2016
- ↑ 8.0 8.1 Glaxosmithkline, "GSK Public policy positions," accessed October 26, 2016
- ↑ Pharmaceutical Research and Manufacturers of America, "Members," accessed October 26, 2016
- ↑ Follow the Money, "Proposition 078," accessed October 7, 2016
- ↑ Glaxosmithkline, "Corporate executive team," accessed October 7, 2016
| |||||||
